Michael J. Fox’s Parkinson’s battle: 5 key moments from his journey

Here are some major moments from Michael J. Fox's Parkinson’s journey

Michael J. Fox’s Parkinson’s battle: 5 key moments from his journey
Michael J. Fox’s Parkinson’s battle: 5 key moments from his journey

Michael J. Fox has spent decades navigating Parkinson’s disease while continuing to shape the conversations about the condition.

The Family Ties star was diagnosed with the neurological disorder at the age of 29. He eventually turned his experience into a significant advocacy and research effort.

Here are some major moments from his Parkinson’s journey.

1. He was diagnosed at 29

Fox was diagnosed with early-onset Parkinson’s disease in 1991 while filming Doc Hollywood. Initially, he experienced a jerky finger ahead of consulting a neurologist.

At the time, he was only 29 and already a major Hollywood star.


2. He kept the diagnosis private

Initially, the Spin City alum chose not to publicly disclose about his condition. However, he continued to amaze fans with his phenomenal acting skills in televisions and films.

Following years of his diagnosis in 1998, he decided to publicly reveal about his condition.

3. He founded a Parkinson’s research foundation

In 2000, Fox established the Michael J. Fox Foundation for Parkinson’s Research. The organization heavily funded Parkinson's research, aiming for the better treatments and a cure.

4. His acting career changed

Fox eventually stepped away from full-time acting as Parkinson’s symptoms became more difficult to manage.

Later on, he returned to television, including a role in The Michael J. Fox Show. In 2026, he also appeared in Shrinking, connecting his real-life experience with the show’s Parkinson’s storyline.

5. His advocacy continues

Fox continues to support Parkinson’s research and awareness. In September 2026, he received the Lasker-Bloomberg Public Service Award for his advocacy and contributions to Parkinson’s research.

Moreover, the foundation launched a $2.5 billion campaign to accelerate research and treatment development.